MedTrace Logo

Efficacy and Safety of ATL-962 in Obese Diabetics

NCT00156897 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2006-08-29

No results posted yet for this study

Summary

The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients

Conditions

  • Non-Insulin-Dependent Diabetes Mellitus
  • Obesity

Interventions

DRUG

ATL-962

DRUG

Orlistat

Sponsors & Collaborators

  • Alizyme

    lead INDUSTRY

Principal Investigators

  • Peter Kopelman · Queen Mary's School of Medicine & Dentistry, London, UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2005-10-31

Countries

  • Denmark
  • Finland
  • Netherlands
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00156897 on ClinicalTrials.gov